SE9101341D0 - NEW MEDICINAL USE - Google Patents

NEW MEDICINAL USE

Info

Publication number
SE9101341D0
SE9101341D0 SE9101341A SE9101341A SE9101341D0 SE 9101341 D0 SE9101341 D0 SE 9101341D0 SE 9101341 A SE9101341 A SE 9101341A SE 9101341 A SE9101341 A SE 9101341A SE 9101341 D0 SE9101341 D0 SE 9101341D0
Authority
SE
Sweden
Prior art keywords
medicinal use
new medicinal
igf
nerve regeneration
new
Prior art date
Application number
SE9101341A
Other languages
Swedish (sv)
Inventor
M Lake
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9101341A priority Critical patent/SE9101341D0/en
Publication of SE9101341D0 publication Critical patent/SE9101341D0/en
Priority to AU17406/92A priority patent/AU1740692A/en
Priority to PCT/SE1992/000275 priority patent/WO1992019256A1/en

Links

Abstract

The use of IGF-II for preparing a medicament for nerve regeneration; and a method for medical treatment resulting in nerve regeneration, comprising the step of administering to patient in need of such treatment an effective amount of IGF-II.
SE9101341A 1991-05-03 1991-05-03 NEW MEDICINAL USE SE9101341D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9101341A SE9101341D0 (en) 1991-05-03 1991-05-03 NEW MEDICINAL USE
AU17406/92A AU1740692A (en) 1991-05-03 1992-04-27 New medicinal use
PCT/SE1992/000275 WO1992019256A1 (en) 1991-05-03 1992-04-27 New medicinal use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101341A SE9101341D0 (en) 1991-05-03 1991-05-03 NEW MEDICINAL USE

Publications (1)

Publication Number Publication Date
SE9101341D0 true SE9101341D0 (en) 1991-05-03

Family

ID=20382638

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9101341A SE9101341D0 (en) 1991-05-03 1991-05-03 NEW MEDICINAL USE

Country Status (3)

Country Link
AU (1) AU1740692A (en)
SE (1) SE9101341D0 (en)
WO (1) WO1992019256A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310049D0 (en) * 1993-05-12 1993-06-30 Cancer Res Campaign Tech Growth factor effects
WO1995013823A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
EP0484416A1 (en) * 1989-07-27 1992-05-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation of nerve growth factor synthesis in the central nervous system

Also Published As

Publication number Publication date
WO1992019256A1 (en) 1992-11-12
AU1740692A (en) 1992-12-21

Similar Documents

Publication Publication Date Title
PT97552A (en) METHOD FOR PREPARING FORMS OF DOSAGE FOR THE ADMINISTRATION OF DRUGS FOR THE TREATMENT OF PARKISON'S DISEASE
ES2000428T3 (en) PROCEDURE FOR PRODUCING A MEDICATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CONTAINING GALANTAMINE, AND CORRESPONDING MEDICAL DEVICE.
ES2040232T3 (en) MEDICINAL PREPARATIONS FOR ORAL ADMINISTRATION CONTAINING A SINGLE DOSE OF 10 TO 240 MG OF DIHIDROPIRIDINA.
HU9300636D0 (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
SE9401406L (en) Pharmaceutical products for the cure of tumor diseases as well as a method for the preparation thereof
DE69132688T2 (en) METHOD FOR TREATING AND PREVENTING TYPE-1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
PT913156E (en) USE OF PROTEIN C ACTIVATED TO TREAT HYPERCERAGULATE STATES ASSOCIATED WITH SEPSIA
KR950703951A (en) ANTIPYRETIC AND ANALGESIC METHODS AND COMPOSITIONS CONTAINING OPTICALLY PURE R-KETOROLAC
HU9301253D0 (en) Medical preparative applicable for treatment of enlarged time of coagulation
HU910979D0 (en) Process for the prodiction of medical preparations with n-neuropeptide-antagonistic effect, containing guanidine derivatives
HRP920834B1 (en) A method for producing an administration and/or dosage form for pharmaceutical active substances using a printing method
RU93032613A (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION
DK0668077T3 (en) Products containing G-CSF and TNF-binding protein
DE69200711D1 (en) Pharmaceutical compositions containing fluticasone propionate and oxikonazole or its salt for topical use.
SE9101341D0 (en) NEW MEDICINAL USE
IT1159042B (en) MEDICAL INFUSER DEVICE IMPLANTABLE IN THE BODY OF THE PATIENT
SE9101840D0 (en) NEW MEDICINAL USE
AU4058789A (en) Medicinal drug, method of treatment of human diseases therewith, and method and device for producing and preserving thereof
SE9000207D0 (en) MEDICINAL PRODUCTS AND THE USE OF THE SAME
NO890997L (en) APPLICATOR FOR SKIN CARE, SKIN CARE AND MEDICAL SALVATION.
AU1458995A (en) Device for extracting automatically the needle of a syringe for medical or paramedical use, and particularly, in dentistry
NO984196L (en) Procedure for the treatment of substance abuse
IT1111893B (en) CHAIR FOR MEDICAL TREATMENT, IN PARTICULAR DENTAL CHAIR
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
RU94000695A (en) Agent showing antiallergic action